Portland State University and VA Portland Health Care System — T111 Antimalarial Program
Researchers at Portland State University and the VA Portland Health Care System are developing T111 and its prodrugs as antimalarial medicines active against the blood, liver, dormant liver, and mosquito stages of the malaria parasite.
What they do
Researchers at Portland State University and the VA Portland Health Care System are developing T111 and its prodrugs as antimalarial medicines active against the blood, liver, dormant liver, and mosquito stages of the malaria parasite.1 T111 is active against drug-resistant parasites, including artemisinin-resistant clinical isolates, and works through a mechanism distinct from current antimalarials.1 The program's R&D is jointly based in Portland, Oregon, with in vivo blood-stage studies conducted at the VA.1 The work is in the development stage, with T111 and its prodrugs in preclinical development.1
- Portland, OR2,1Research and development
In the field and in development
Partnerships in 2 endemic countries
Who they work with in the United States
- In the atlas
- In the atlas
- In the atlas
- In the atlas
- In the atlas
- In the atlas
- In the atlas
- In the atlas

